a a study A publication in the New England Journal of Medicine revealed that Pfizer’s first dose of coronavirus vaccine already provides 92.6% efficacy, so its authors, Danuta Skowronski and Gaston De SerresUrging governments to delay the second injection until the main high-risk groups receive at least the first.
The investigation, according to those who signed it, derives from documents Pfizer provided to the United States Medicines Regulatory Authority. “With such a first preventive dose, the benefits from poor vaccine supply can be maximized by delaying the second doses until all members of the priority group are offered at least one dose. There may be uncertainty about the duration of protection with a single dose, but a second dose is given within a month. After the first dose, as recommended, It offers few additional benefits in the short termWhile people at high risk who would have received a dose, they indicate, as reported by Reuters. “Given the current shortage of vaccines, delaying the second dose is a matter of national security.” The researchers add.
The researchers note that this small “additional” benefit means that seven days after the second injection, immunity rises to 94.8%, just over two points.
In response, Pfizer asserted that it has not yet studied other alternative methods for the current injection – two injections – and states that the decision on whether to give the dosing depends on the health authorities.